The Healthy Moms and Babies Act (S 2289) aims to improve maternal and infant health outcomes by strengthening Medicaid and CHIP programs. It requires states to report on maternal health quality measures, establishes a new "maternity health home" option for coordinated care during pregnancy and postpartum, and mandates studies on reducing cesarean sections and expanding doula services under Medicaid. The bill also requires states to collect data on social determinants of health affecting pregnant and postpartum women and provides guidance for reducing maternal mortality and severe morbidity. These provisions directly affect pregnant and postpartum women enrolled in Medicaid, healthcare providers, and state Medicaid programs.
This bill requires Medicaid and CHIP programs to cover tobacco cessation counseling and FDA-approved medications (including nonprescription options) with no out-of-pocket costs for enrollees. It directly affects low-income individuals using tobacco products who are enrolled in Medicaid or CHIP. Key mechanisms include a temporary 90% federal funding share for these services for five years, prohibitions on prior authorization for cessation drugs, and requirements for states to promote these services through outreach campaigns. The law also mandates states to monitor and increase awareness of these covered benefits among tobacco users and healthcare providers.
HR 4104 would expand access to Medicaid, CHIP, and Affordable Care Act (ACA) health coverage for immigrants lawfully present in the U.S., including those with deferred action or pending immigration applications. It removes state-level barriers to Medicaid/CHIP eligibility for lawfully present individuals, treats Federally authorized presence as "lawfully present" for ACA subsidies, and allows states to choose to cover undocumented individuals through Medicaid or CHIP. The bill also extends these changes to Medicare Part A and Part B, ensuring lawfully present immigrants qualify for coverage and subsidies under existing programs. These provisions apply to all federally funded health programs and take effect in 2026 for most ACA-related changes.
This bill requires hospitals and obstetric providers to disclose policies on providing life-saving care to premature infants, directly affecting parents expecting premature births and healthcare facilities. Hospitals must publicly state if they have a minimum gestational age for treatment, whether care decisions are case-by-case, and transfer plans for infants needing higher-level care. Obstetric providers must share these policies with patients during the first prenatal visit. Non-compliant hospitals and providers risk losing federal Medicaid and CHIP funding starting January 2026. The law aims to ensure transparency about neonatal care options before delivery.
This bill reauthorizes and updates federal programs for newborn screening, primarily affecting infants, children with genetic conditions, and their families. It increases annual funding for screening programs to $20.8 million (2026-2030) and research to $22.25 million, requiring states to develop parent education materials on screening follow-up and treatment. Key provisions include creating a public clearinghouse for screening data, improving coordination between state health programs, and mandating that research on genetic testing must consult with state health departments. The bill also updates deadlines for advisory committee work and technical assistance for screening panels through 2030.
HRES 955 is a symbolic House resolution recognizing the importance of maintaining U.S. leadership in ending pediatric HIV/AIDS globally. It affirms support for existing programs like PEPFAR and the Global Fund, which provide critical prevention services (e.g., antiretroviral prophylaxis for pregnant women) and treatment for children. The resolution specifically calls for continued commitment to closing the treatment gap for children, expanding access to long-acting prevention methods, and advancing the Global Alliance to End AIDS in Children by 2030. As a recognition measure, it does not create new laws or allocate funding but underscores ongoing U.S. efforts to prevent mother-to-child transmission and improve pediatric HIV outcomes.
The Protecting Free Vaccines Act of 2025 requires health insurance plans, Medicare, Medicaid, and the Children's Health Insurance Program (CHIP) to cover recommended vaccines without cost-sharing (like copays or deductibles). It mandates coverage for vaccines recommended by the federal Advisory Committee on Immunization Practices (ACIP) as of October 25, 2024, including any updated versions approved under existing rules. This coverage requirement applies until December 31, 2029 for Medicaid and CHIP, and until January 1, 2030 for other plans. The law does not apply to vaccines given during the minimum interval between doses for that specific vaccine.
HR 3792, the KIDS Act, prohibits healthcare providers participating in Medicare, Medicaid, or CHIP from requesting minors' gender identity or sexual preference on intake forms or during healthcare enrollment. The bill bans such requests for non-essential information unrelated to a minor's medical diagnosis, treatment, or prevention of health conditions. Providers must stop collecting this data 180 days after the bill's enactment, with a new reporting system for violations to be established by the HHS within the same timeframe. This directly affects healthcare providers serving children under 18 in federally funded health programs.
HR 3769, the Dependent Income Exclusion Act of 2025, modifies tax rules to help families qualify for health insurance premium tax credits. It excludes certain income earned by dependents under age 18, or dependents aged 18-24 enrolled in approved education or job-training programs (like those under the Workforce Innovation Act), from being counted toward household income for credit calculations. The exclusion is limited to 15% of a family’s total income, and in states that haven’t expanded Medicaid, it cannot reduce household income below 100% of the federal poverty line. The bill amends the Internal Revenue Code and Affordable Care Act to implement these changes, affecting families claiming health insurance tax credits.
This bill requires Medicare, Medicaid, and CHIP to cover cancer diagnostic and laboratory tests (like genetic sequencing for cancer diagnosis and treatment monitoring) for patients. It defines these tests specifically and sets rules: Medicare pays 80% (or 100% for certain cases) of the test cost without deductibles, while Medicaid must cover them starting in 2027 and CHIP must cover them for children and pregnant women starting in 2025. Tests can only be provided once at diagnosis, once for recurrence, and as needed for treatment planning. The bill directly affects cancer patients enrolled in these federal health programs.
